Robert Gutman, MD
Urogynecology and Reconstructive Pelvic Surgery · Baltimore, MDNPI 1043268501
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,646 of the $28,406 with a category attached, or 69.2%. Boston Scientific accounts for 65.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $9,557 and has fallen 92.6% since, to $704 in 2025.
Across 132 payments — averaging $215.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$19K
- Coloplast$8K
- Axonics, Inc.$1K
- Sumitomo Pharma America, Inc.$222
- AbbVie$221
- Caldera Medical, Inc$134
- plus $336 from 10 others
Across 10 payments — averaging $5891.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$59K
What the payments were for
- Consulting fees$19,64669%
- Travel & lodging$3,04711%
- Food & beverage$5,50719%
- Education$1511%
- Gifts$360%
- Entertainment$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 49 | $18,557 |
| Coloplast | 27 | $7,809 |
| Axonics, Inc. | 20 | $1,127 |
| Sumitomo Pharma America, Inc. | 10 | $222 |
| AbbVie(2 entities) | 6 | $221 |
| Caldera Medical, Inc | 5 | $134 |
| Urovant Sciences Inc | 6 | $127 |
| Convatec Inc. | 1 | $34 |
| Contura, Inc. | 1 | $30 |
| Medtronic | 1 | $26 |
| Avita Medical Americas, LLC | 1 | $22 |
| Bluewind Medical | 1 | $22 |
| Valencia Technologies Corporation | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Provepharm Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$5,899
- GENERAL FEMALE SUI$5,073
- GENERAL PELVIC ORGAN PROLAPSE$2,719
- GENERAL - THERAPIES$1,283
- Axonics$858
- Advantage System$341
- Solyx SIS System$337
- SOLYX$122
- ADVANTAGE FIT$116
- UPSYLON$110
- BOTOX$108
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 124 | $125,693 |
| MyrbetriqMirabegron | 98 | $98,651 |
| Trospium Chloride ErTrospium Chloride | 84 | $20,346 |
| Estradiol | 149 | $10,686 |
| Trospium Chloride | 50 | $3,813 |
| Solifenacin Succinate | 75 | $3,596 |
| Clobetasol Propionate | 19 | $930 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $379 |
| Cephalexin | 30 | $350 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $276 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $272 |
| Oxycodone Hcl | 27 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $222 | $125,693124 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $98,65198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Baltimore
- Joan BlomquistBaltimore$4K
- Aparna RamaseshanBaltimore$3K
- Neha GaddamBaltimore$2K
- Tola FashokunBaltimore$1K
- Victoria HandaBaltimore$140
- Mava Robinson-WaltonSilver Spring$257K
- Daniel GruberBethesda$91K
- Anita Pillai AllenSilver Spring$38K
- Aisha TaylorHanover$29K
- Yong ZhengBowie$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.